Improved Effects of Myo-inositol in Association With Alpha-lactalbumin in PCOS Women
| Registry | NCT03422289 |
|---|---|
| Status | Completed |
| Phase | Not applicable |
| Study type | Interventional; non randomized, sequential, masking: none, treatment |
| Enrollment | 37 (Actual) |
| Sponsor | Lo.Li.Pharma s.r.l (Industry) |
| Conditions | Polycystic Ovary Syndrome |
| Interventions | myo-inositol plus folic acid, myo-inositol plus folic acid plus alpha-lactalbumin (Dietary supplement) |
| Dates | start 2016-11-02, primary completion 2017-10-12, completion 2017-12-15, first posted 2018-02-05, last updated 2018-02-06 |
| Locations | 1 site in Italy |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Polycystic Ovary Syndrome All trials of myo-inositol plus folic acid All trials of myo-inositol plus folic acid plus alpha-lactalbumin
PCOS patients are initially treated with 2 g myo-inositol and 0.2 mg folic acid, two times per day by oral route, for three months. Among them, the subjects who have not ovulated despite this treatment are administered with 2g myo-inositol and 0.2 mg folic acid plus 50 mg α-lactalbumin for three months. Most of them improve and achieve ovulation. Therefore, the combination of α-lactalbumin with myo-inositol allows to get a significant result in the treatment of PCOS patients.
Polycystic ovary syndrome is a complex chronic condition inducing several related disorders, such as subfertility and pregnancy complications. So far myo-inositol, successfully used in PCOS, has not been always effective in all patients. Aiming at overcoming this drawback, we tested a new formulation with myo-inositol and α-lactalbumin, in consideration of the effects exerted by α-lactalbumin in favoring molecule passage among body compartments, and also in consideration of its anti-inflammatory activity.
Only PCOS patients, according to Rotterdam ESHRE-ASRM criteria, with anovulation and infertility > 1 year, were included in the study. Following a treatment with 2 g myo-inositol and 0.2 mg folic acid, a part of them are resistant and do not ovulate.
These non-responders to myo-inositol alone undergo the second phase of the study, receiving 2g myo-inositol and 0.2 mg folic acid plus 50 mg α-lactalbumin for three months. After this combined treatment, the majority of them ovulate, showing a hormone and lipid profile improvement. In addition, myo-inositol plasma levels at the end of the treatment are significantly higher than at baseline and comparable to those patients who respond positively to myo-inositol alone.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Myo-inositol + folic acid | Experimental | Dietary Supplement: myo-inositol plus folic acid | 2 g myo-inositol and 0.2 mg folic acid orally twice a day for three months, in order to induce ovulation. |
| Myo-inositol + folic a. + α-lactalbumin | Experimental | Dietary Supplement: myo-inositol plus folic acid plus alpha-lactalbumin | 2 g myo-inositol and 0.2 mg folic acid plus 50 mg α-lactalbumin, twice a day for three months in order to test if α-lactalbumin addition allows to induce ovulation |
Sex: Female, ages: 20 Years to 35 Years
Inclusion Criteria: * patients affected by PCOS according to Rotterdam ESHRE-ASRM criteria, with anovulation and infertility > 1 year Exclusion Criteria: * presence of other conditions causing ovulatory dysfunction, such as hyperprolactinemia or hypothyroidism, or androgen excess, such as adrenal hyperplasia or Cushing's syndrome, and also in the case of intake of other drugs that can potentially influence the ovulation.
| Facility | City | Country | Status |
|---|---|---|---|
| Department of Woman Health and Reproductive Medicine of Santo Spirito Hospital | Rome | Italy |